

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND (2) CONTINUED SUSPENSION OF TRADING

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 31 July 2024, 30 September 2024 and 4 October 2024 (collectively the “**Announcements**”) pursuant to, among other things, Rules 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

The purpose of this announcement is to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the latest development of the Group’s business operations and the progress of actions recently taken by the Company in connection with fulfilling the Resumption Guidance.

UPDATE ON BUSINESS OPERATIONS

The Company is principally engaged in (i) the trading of footwear products; (ii) the trading of healthcare products; (iii) the provision of financial services; and (iv) the provision of online medical services. As at the date of this announcement and as further disclosed below, the Group’s business in the trading of healthcare products and the provision of financial services and online medical services is operating at a minimal level.

The Online Medical Services Business: Bankruptcy Proceedings of Shangying Medical

In relation to the online medical services business, Shangying Internet Medical (Shanghai) Co. Limited (商贏互聯網醫療(上海)有限公司) (an indirect non-wholly owned subsidiary of the Company) (“**Shangying Medical**”), being the major business entity for the provision of online medical services, has entered into bankruptcy proceedings in the PRC. According to Deloitte Touche Tohmatsu Certified Public Accountants LLP (the “**Administrator**”), the Mainland bankruptcy administrator of Shangying Medical, due to the uncertainty regarding the time required for the auction of Shangying Medical’s assets, the Administrator is currently unable to make a concrete assessment of the expected completion time for the bankruptcy proceedings.

The Online Medical Services Business: Disposal of Shang Ying Trade

On 30 December 2024, the Company entered into a sale and purchase agreement with an independent third party, pursuant to which the Company agreed to sell the entire issued share capital of Shang Ying International Trade Holdings Limited (“**Shang Ying Trade**”) to the purchaser at a nominal consideration of HK\$1 (the “**Disposal**”). Prior to the Disposal, Shang Ying Trade was a wholly-owned subsidiary of the Company. It is an investment holding company, mainly holding a company incorporated in the PRC which provides online medical services. The Disposal was conducted by the Company with a view to improving the Group’s overall business operations and financial position, having considered that Shang Ying Trade had been loss-making over the years and was operating at net liabilities. The Disposal was completed on 30 December 2024.

Termination Notice in relation to the Loan Deed

Reference is made to the announcement of the Company dated 1 August 2018 in relation to a loan and option deed (the “**Loan Deed**”) entered into between Shang Ying Health Holdings Limited (an indirect wholly-owned subsidiary of the Company) (“**SY Health**”) (as lender) and Century Health Holdings Co., Limited (“**Century Health**”) (as borrower) on 1 August 2018 for the provision of a loan in the total sum of AUD8,000,000 (the “**Loan**”). Since no repayments have been received for the overdue portions of the Loan up to the date of this announcement, constituting an event of default under the Loan Deed, SY Health has, on 12 December 2024, issued a termination notice to Century Health in accordance with the Loan Deed and has engaged a legal adviser to handle the recovery of the Loan.

Save as disclosed above, notwithstanding the suspension of trading in the Company’s shares, up to the date of this announcement, the Group is carrying on its business operations as usual in all material respects and will continue to assess and monitor its financial position and business operations.

The Company will publish further announcement(s) of the status and development of (i) the bankruptcy proceeding of Shangying Medical; and (ii) the recovery of the Loan as and when appropriate.

UPDATE ON PROGRESS OF RESUMPTION

Below is the Resumption Guidance of the Stock Exchange and the Company's resumption plan with details of actions that the Company has taken or intends to take as well as the expected timeframe in fulfilling the Resumption Guidance to resume trading in its shares:

Resumption Guidance	Update on resumption progress and the expected timeline
(i) publish all outstanding financial results required under the Listing Rules and address any audit modifications	<p>As at the date of this announcement, the auditor of the Company is in the process of conducting the relevant audit procedures for the audit of the annual results of the Company for the year ended 31 December 2023 (the “2023 Annual Results”).</p> <p>Based on information currently available, it is expected that the 2023 Annual Results, the interim results of the Company for the six months ended 30 June 2024 (the “2024 Interim Results”) and the annual results of the Company for the year ended 31 December 2024 (the “2024 Annual Results”) would be published by the Company by or around 31 March 2025.</p>
(ii) demonstrate the Company's compliance with Rule 13.24	<p>Since the suspension of trading in the Company's shares on 2 April 2024 and up to the date of this announcement, save as disclosed in this announcement, the business operations of the Group have operated as usual in all material respects.</p> <p>The Company's compliance with Rule 13.24 of the Listing Rules would be assessed with the publication of the 2023 Annual Results and the 2024 Annual Results.</p>
(iii) inform the market of all material information for the Shareholders and potential investors to appraise the Company's position	<p>Since the suspension of trading in the Company's shares on 2 April 2024, the Company has kept the Shareholders and potential investors informed of all material information in relation to, among others, the Resumption Guidance and other relevant updates and progress by way of announcements.</p> <p>The Company will continue to keep the Shareholders and potential investors informed of any relevant material developments by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules.</p>

The expected timeline as disclosed above is indicative only and may or may not be updated depending on, among others, any additional audit procedures. The Company will publish further announcement(s) of the status and developments of the Company as and when appropriate, as well as announce quarterly updates on the development of its resumption status in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the Resumption Guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.

By Order of the Board
TATA Health International Holdings Limited

Hong Kong, 3 January 2025

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.